Anavex comments on failing of Pfizer and Medivation’s Alzheimer’s Investigational drug Dimebon Anavex Lifestyle Sciences Corp http://suhagrastore.com . issued a statement following a announcement from Pfizer and Medivation that their investigational Alzheimer’s drug Dimebon did not satisfy either its co-main or secondary endpoints compared to placebo during pivotal Stage 3 clinical trials. While this is disappointing for the Alzheimer’s community, there were many doubts expressed about Dimebon. These doubts have been documented by leading researchers, including ex-Nationwide Institutes of Wellness staffers.
Grant support was provided by Novartis Pharmaceuticals and was supplemented in the United Kingdom by the infrastructure of the Nationwide Cancer Study Network. Novartis Pharmaceuticals donated research items of zoledronic acid. The authors developed the study concept, wrote the protocol, and performed and reviewed all analyses. The scholarly research was conducted in accordance with the protocol, with amendments to reduce the risk of osteonecrosis of the jaw also to inform both individuals and dental practitioners of this risk. The first writer wrote the 1st draft of the manuscript, and all authors were involved with approval and revision of the manuscript. Novartis Pharmaceuticals was given an opportunity to touch upon the manuscript, but all decisions on submission of the manuscript for publication were made by the authors and the trial steering committee.